NEW YORK, NY / ACCESSWIRE / August 31, 2016 / Abercrombie & Fitch Co. (NYSE: ANF) shares fell 20.29 percent to close at $18.29 a share Tuesday. The stock traded between $18.06 and $19.51 on volume of 23.02 million shares traded. The stock appears to be facing some resistance at $18.45 and $19.42 with some support at $16.80. On Tuesday, the retailer reported earnings for the second quarter that fell short of expectations. Abercrombie’s sales dropped for the 14th straight quarter and comparable sales fell a slightly steeper-than-expected, mainly due to lower traffic, including from tourists, at its flagship stores. The company no longer expects comparable sales to improve this year.

Register with us now for your free membership and gain access to our latest reports at: www.rdinvesting.com/subscribe-today/.

“Our results for the quarter were largely in line with the expectations we set on last quarter’s earnings call. Flagship and tourist locations continued to account for the vast majority of the comparable sales decline as traffic remained a significant headwind. We were encouraged, however, by strong growth in the direct-to-consumer business, both domestically and internationally, and by a comparable sales recovery in the Hollister European business, including in the U.K.,” commented Arthur Martinez, Executive Chairman.

Get Your Up-To-Date Abercrombie & Fitch Research Report at www.rdinvesting.com/company/ANF.

A Closer Look at Abercrombie & Fitch’s Earnings

Abercrombie & Fitch reported revenues totaled $783.2 million for the second quarter of 2016, down by 4.0 percent when compared to a year ago. Comparable sales for the quarter fell 7 percent at Abercrombie stores and 2 percent at its sister chain Hollister, for an overall decline of 4 percent.

The company reported a GAAP net loss per diluted share of $0.19 for the second quarter ended July 30, 2016, compared to a GAAP net loss per diluted share of $0.01 for the second quarter last year.

Get Your Up-To-Date Abercrombie & Fitch Research Report at www.rdinvesting.com/company/ANF.

Going Forward

Abercrombie& Fitch expects “comparable sales to remain challenging through the second half of the year, with a disproportionate effect from flagship and tourist locations”. The company plans to open approximately 15 new stores in fiscal 2016, approximately 10 in international locations primarily in China and 5 in the U.S. 60 of the company’s U.S. locations are expected to close during the fiscal year through natural lease expirations.

“As we look to the rest of the year, we now expect flagship and tourist locations will continue to weigh on the business. Recognizing we are in a challenging environment, we are confident, however, that we are focusing on the right priorities and we expect to see traction in our business as we introduce new product and invest in marketing to drive awareness and relevance for our brands,” commented Arthur Martinez.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Hemal K. Gandhi, a CFA® charter holder. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com

ReleaseID: 444565

LONDON, UK / ACCESSWIRE / August 31, 2016 / Active Wall St. announces its post-earnings coverage on Autodesk, Inc. (NASDAQ: ADSK). The company reported second quarter fiscal 2017 financial results on 25th August, 2016. The pioneering maker of computer-aided design software delivered a surprise profit with analysts had been expecting a loss, and the company also provided better-than-expected outlook for the current quarter. Register with us now for your free membership at: http://www.activewallst.com/register/.

Today, AWS is promoting its earnings coverage on ADSK. Get our free coverage by signing up to http://www.activewallst.com/registration-3/?symbol=ADSK.

Earnings Numbers

For the three months ended on July 31, 2016, Autodesk reported net loss of $98.2 million, or $(0.44) per share, compared with a loss of $268.6 million, or $(1.18) per share in the corresponding year earlier quarter. Excluding stock-based compensation and other items, Autodesk reported earnings of $0.5 per share, down from $0.19 per share a year earlier. Revenue declined 10% to $551 million in Q2 FY17, or 6% when adjusted for currency fluctuations. Analysts projected a loss of $0.13 per share on revenue of $512 million. The decline in revenues was attributed to a 21.3% y-o-y decline in License revenues to $228.7 million from $290.5 million in Q2 FY16.

Autodesk’s total subscriptions rose by 109,000 from Q1 FY17 to 2.82 million. The company expects to add 475,000 to 525,000 subscriptions for the year. Autodesk also noted that total annualized recurring revenue (ARR) was $1.47 billion, an increase of 10% compared to Q2 FY16 and 14% on a constant currency basis. The company stated that new model ARR surged 82% on y-o-y basis to 371 million. The San Rafael, California headquartered company had earlier warned investors that sales would be impacted in the short-term due to its shift to ARR model from the traditional perpetual license model. Gross profit margin narrowed to 84.5% from 84.7% in the year ago period, while operating expenses rose 3%.

“We posted terrific second quarter results driven by growth in new model subscriptions, the end of perpetual license sales, and diligent cost control,” said Carl Bass, Autodesk’s president and CEO, “We’ve now seen several quarters of strong growth from our new model subscriptions, as our customers and partners embrace a model that has greater flexibility and a better user experience. Finally, we continued to extend our leadership in the cloud during a quarter that delivered our largest-ever increase in cloud subscriptions led by BIM 360 and Fusion 360.”

Segment wise

During Q2 FY17, revenues from Autodesk’s Architecture, Engineering and Construction business segment rose 8% to $253 million from the year earlier quarter. Manufacturing revenues grew 3% on y-o-y basis to $177 million. However the company’s Platform Solutions and Emerging Business segment sales plunged 47% to $86 million from the year ago period. Revenue from Autodesk’s Media and Entertainment segment slumped 16% on a y-o-y basis to $34 million.

On Geographical basis, revenues in Q2 FY17 from Autodesk’s Americas region fell 2% on y-o-y basis to $230 million. EMEA revenues declined 2% to $221 million, while sales in the APAC region tumbled 32% to $100 million.

Balance Sheet

As of July 31, 2016, Autodesk had cash and cash equivalents of $1.47 billion compared with $1.35 billion as on January 31, 2016. The company’s deferred revenue increased 23% to $1.52 billion compared to $1.24 billion in the second quarter last year.

Outlook

For Q3 FY17, Autodesk is projecting an adjusted loss of $0.22 per share to $0.27 per share with revenues in the range of $470 million to $485 million, compared to analysts’ estimate of a loss of $0.28 per share on revenue of $468.5 million.

For FY 2017, the company is projecting revenue of $2 billion to $2.05 billion, up from the previous forecast of $1.95 billion to $2.05 billion, and above analysts’ estimate of $1.99 billion. Autodesk is expecting net loss in the range of $0.55 per share to $0.70 per share, better than the prior forecast of net loss of $0.70 to $0.95 per share and market estimate of $0.82 per share.

Stock Performance

On August 30, 2016, Autodesk’s shares declined marginally by 0.42% to close the trading session at $ 68.03. A total volume of 2.4 million shares were traded during the session, which was above the 3 months average volume of 1.65 million. The company’s stock price has gained 13.88% in the past one month and has advanced 45.52% in the past 12 months.

Active Wall Street:

Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

AWS has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third party research service company (the “Reviewer”) represented by a credentialed financial analyst, for further information on analyst credentials, please email info@activewallst.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@activewallst.com

Phone number: 1-858-257-3144

Office Address: 3rd floor, 207 Regent Street, London, W1B 3HH, United Kingdom

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active Wall Street

ReleaseID: 444568

LAS VEGAS, NV / ACCESSWIRE / August 31, 2016 / Outside of the energy sector, the past year, there has not been any sector under more pressure than biotechnology. As an example of the bearish bias, the ProShares Ultra NASDAQ Biotechnology ETF (NASDAQ: BIB) has slumped from a record high last July at $106.10 to a low of $33.97 late in June, representing a top-to-bottom decline of 68%. For the most part, biotechs of all sizes have felt the pain. Markets are always cyclical and I believe the biotech beat down is reaching its bottom and will soon begin to reverse the trend. From a technical perspective, I think that BIB breaking over $50 again will be a sign of the reversal (it’s currently around $43).

With the recent drop in the value of Endonovo Therapeutics (ENDV), the company is worthy of additional due diligence. This company is working on the cutting edge of biotechnology in a field known as bioelectronics, which is the study and application of electronics in medicine and biological processes. It is a field that brings together engineering, materials science, nanotechnology, medicine and biology to explore and harness molecular and cellular processes under the control or influence of electrical signals. There are far reaching applications of these technologies from biosensors and the ability to control stem cells and biomolecules through electronic circuits to developing implantable and non-implantable devices that can control organ functions and lower inflammation. This is why GlaxoSmithKline is teaming up with Alphabet, Google’s parent company, to form Galvani Bioelectronics in order to research, develop and commercialize the use of electrical signals to treat diseases. The companies will invest up to $715 million over 7 years to meet the goal of producing tiny implantable devices to treat diseases like arthritis, diabetes and asthma within a decade.

Endonovo is developing electronic devices to produce more potent stem cells and non-invasive electroceutical devices to treat inflammation in vital organs. One of Endonovo’s lead programs is the Immunotronics platform, a non-invasive, non-implantable electroceutical device for treating and/or preventing vital organ failure resulting from an out of control immune response to infection or injury. The initial focus of the company is to use the Immunotronics platform to treat acute and chronic inflammatory conditions of the liver, such as acute liver injury, fulminant hepatic failure and Non-Alcoholic Steatohepatitis (NASH).

Here are a few highlights we believe make ENDV an extremely interesting company to watch to bounce with biotech:

Endonovo’s technology was shown to be a very potent non-invasive, anti-inflammatory device in a pre-clinical, pharmaceutical industry gold standard model of acute inflammation
The Company just receive a patent covering the production of biologics, like G-CSF, GM-CSF, IL-2 and EPO using its novel bioreactors for growing stem cells
ENDV just filed a patent application covering the use of biologics produced by its Cytotronics™ platform for the treatment of chemical and radiation injuries, like chemotherapy and exposure to radiation
Immunotronics™ technology is completely non-invasive, whereas ENDV’s competitors are largely pursuing invasive implantable devices
Therapies target large unmet clinical needs in treating and preventing organ failure and other inflammatory conditions in vital organs

This week is a great time to consider taking a long look at ENDV.

After releasing financials and news last week, a few biotechs have been running:

Ocular Therapeutix, Inc. (OCUL) released its Q2 financials and has been on quite a run since, culminating in Monday’s large price jump.

Lpath, Inc. (LPTN) just filed an S-3 registration statement to raise up to $10 million in equity financing to pursue strategic mergers or acquisitions. The stock has nearly double since last week and may have some room to run if LTPN announces a deal like STEM did the week before.

StemCells, Inc. (STEM) announced a strategic merger with Microbot Medical Ltd., an Israel-based developer of robotics-based medical devices and has since been an incredible run.

Eleven Biotherapeutics, Inc. (EBIO) investors reacted extremely favorably to EBIO’s Q2 financials.

Legal Disclaimer

Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. ACR Communication, LLC. which owns Microcapspeculators.com, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. ACR Communication, LLC. which owns, Microcapspeculators.com may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. ACR Communication LLC. which owns Microcapspeculators.com may be compensated for its services in the form of cash-based compensation or in equity in the companies it writes about, or a combination of the two. For Full Legal Disclaimer Click Here.

SOURCE: ACR Communication, LLC

ReleaseID: 444577

LONDON, UK / ACCESSWIRE / August 31, 2016 / Active Wall St. announces its post-earnings coverage on Pure Storage, Inc. (NYSE: PSTG). The company posted its financial results for the second quarter fiscal 2017 (Q2 FY17) on August 25, 2016. The flash-based storage company reported better-than-expected second quarter earnings readings with its outlook for the October quarter predicting continued progress. Register with us now for your free membership at: http://www.activewallst.com/register/.

Today, AWS is promoting its earnings coverage on PSTG. Get our free coverage by signing up to http://www.activewallst.com/registration-3/?symbol=PSTG.

Earnings Numbers

For the three months ended on July 31, 2016, Pure Storage posted revenue of $163.2 million up 92.8% compared to corresponding prior year’s quarter. Revenue topped analysts’ forecasts of $155 million, driven by repeat purchase rates and growing sales to international customers. For Q2 FY17 the company reported net loss of $59.6 million or $(0.31) per share, lower than net loss of $63.8 million or $(1.89) per share in Q2 FY16. On adjusted basis, Pure Storage reported loss of $(0.16) per share which was less than the estimated loss of $0.23.

Pure storage’s gross margin improved 6.7% compared to 65.2% for the year earlier quarter; up 6.7% y-o-y. Adjusted gross margin came in at 66.3%, up 7.1% on y-o-y basis.

“We are delighted to report another great quarter with record revenue,” Pure Storage CEO Scott Dietzen stated.

Cloud Expanding

The company attributed the growth in business to repeat purchases. The company also noted healthy demand in cloud customers, which was making up 25% of the company’s core business. Pure Storage’s revenue growth was also bolstered by international customers, which account for 25% of the revenue earned by the firm.

During Q2 FY17, Pure Storage started shipping of its new product “FlashBlade”, its second major product line. At the outset, the new product was only available to a select number of customers. FlashBlade has now been dispatched and is on its way to datacenters. Mr. Dietzen emphasized that the company does not see FlashBlade making an impact on revenue for FY 2017; however the company’s management is excited about the range of possibilities FlashBlade is already offering to customers in chip design, genomics and life sciences, big data analytics, software development, Internet of Things, machine learning, and film production.

In Q2 FY16, Pure Storage added more than 350 new customers to its portfolio, increasing its total client base to more than 2,300 firms. Some of the giants that are now doing business with Pure Storage include the University of Tokyo, Sally Beauty Supply, British Airways, and others.

Financials

As of July 31, 2016, Pure Storage had cash and cash equivalents worth $205.81 million compared to cash in hand of $604.74 million as of January 31, 2016.

Outlook

For Q3 FY17, Pure Storage is forecasting revenue to be in the range of $187 million to $195 million versus analysts’ estimate of $190.7 million. Non-GAAP gross margin is expected to be in the range of 64% to 67%, while non-GAAP operating gross margin is projected to be in the range of -17.5% to -13.5%.

Stock Performance

At the closing bell, on August 30, 2016, Pure Storage’ shares were flat for the day, finishing the trading session at $11.69. A total volume of 1.09 million shares were traded for the day. For the past 3 months, the stock gained 3.36%.

Active Wall Street:

Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

AWS has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third party research service company (the “Reviewer”) represented by a credentialed financial analyst, for further information on analyst credentials, please email info@activewallst.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@activewallst.com

Phone number: 1-858-257-3144

Office Address: 3rd floor, 207 Regent Street, London, W1B 3HH, United Kingdom

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active Wall Street

ReleaseID: 444555

LONDON, UK / ACCESSWIRE / August 31, 2016 / Active Wall St. announces the list of stocks for today’s research reports. Pre-market the Active Wall St. team provides the technical coverage impacting selected stocks trading on the Toronto Exchange and belonging under the Healthcare sector. Companies recently under review include Acerus Pharma, Mettrum Health, Aurinia Pharma, and Lattice Biologics. Get all of our free research reports by signing up at: http://www.activewallst.com/register/.

On Tuesday, August 30, 2016, The Toronto Exchange Composite Index closed at 14,684.85, slightly up 0.02% on trading volume of 311,127,368 shares. The TSX Venture Composite Index, on the other hand, dropped 1.93% ending the day at 790.35 on a total volume of 171,696,310 shares traded during the session.

Active Wall St. has initiated research reports on the following equities: Acerus Pharmaceuticals Corporation (TSX: ASP), Mettrum Health Corporation (TSX-V: MT), Aurinia Pharmaceuticals Inc. (TSX: AUP), and Lattice Biologics Ltd. (TSX-V: LBL). Register with us now for your free membership and research reports at: http://www.activewallst.com/register/.

Acerus Pharmaceuticals Corporation (TSX: ASP)

On Tuesday, shares in Mississauga, Canada headquartered Acerus Pharmaceuticals Corp. ended the session 8.57% higher at $0.19 with a total volume of 612,300 shares traded. Acerus Pharmaceuticals’ shares have rallied 90.00% in the last one month and 35.71% in the previous three months. The stock is trading above its 50-day and 200-day moving averages. The company’s 200-day moving average of $0.14 is greater than its 50-day moving average of $0.12. Shares of Acerus Pharmaceuticals, which focuses on developing, manufacturing, marketing, and distributing pharmaceutical products for male hypogonadism, women’s hormone replacement therapy, and female sexual dysfunction in Canada, are trading at a PE ratio of 7.60. See our research report on ASP.TO at: http://www.activewallst.com/registration-3/?symbol=ASP.

Mettrum Health Corp. (TSX-V: MT)

Bowmanville, Canada headquartered Mettrum Health Corp.’s stock finished Tuesday’s session 0.38% higher at $2.63 with a total volume of 329,069 shares traded. Over the past three months and the previous one year, shares of Mettrum Health, which engages in the research, development, production, and distribution of medical cannabis and cannabis products in Canada, have rallied 58.43% and 94.81%, respectively. However, the Company’s stock has fallen by 4.36% in the last one month. The Company’s shares are trading above its 200-day moving average. Mettrum Health’s 50-day moving average of $2.63 is above its 200-day moving average of $1.92. The complimentary research report on MT.V at: http://www.activewallst.com/registration-3/?symbol=MT.

Aurinia Pharmaceuticals Inc. (TSX: AUP)

Victoria, Canada headquartered clinical stage pharmaceutical company, Aurinia Pharmaceuticals Inc.’s stock advanced 2.40%, to close the day at $2.56. The stock recorded a trading volume of 13,236 shares. Shares of Aurinia Pharmaceuticals, which engages in the development of a therapeutic drug to treat autoimmune diseases in Canada, are trading below their 50-day and 200-day moving averages. Moreover, the stock’s 50-day moving average of $3.83 is greater than its 200-day moving average of $3.59. Register for free and access the latest research report on AUP.TO at: http://www.activewallst.com/registration-3/?symbol=AUP.

Lattice Biologics Ltd. (TSX-V: LBL)

On Tuesday, shares in Scottsdale, Arizona headquartered Lattice Biologics Ltd. recorded a trading volume of 48,000 shares, which was higher than their three months average volume of 37,681 shares. The stock ended the day 4.00% lower at $0.24. Shares of Lattice Biologics, which provides personalized/precision medicine for cellular therapies and tissue engineering, have gained 9.09% in the last one month and 26.32% in the previous three months. The Company is trading above its 50-day and 200-day moving averages at $0.22. Get free access to your research report on LBL.V at: http://www.activewallst.com/registration-3/?symbol=LBL.

Active Wall Street:

Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

AWS has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third party research service company (the “Reviewer”) represented by a credentialed financial analyst, for further information on analyst credentials, please email info@activewallst.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@activewallst.com

Phone number: 1-858-257-3144

Office Address: 3rd floor, 207 Regent Street, London, W1B 3HH, United Kingdom

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active Wall Street

ReleaseID: 444559

NEW YORK, NY / ACCESSWIRE / August 31, 2016 / The S&P/TSX Composite Index rose by as much as 0.70 percent in early trading Tuesday before settling to close at 14,684.85, up 0.02 percent and up approximately 0.7 percent in the month of August. Major gains by Potash Corp. of Saskatchewan Inc. and Agrium Inc., who are amidst merger talks, were offset by declines by gold miners. The TSX materials sector was the biggest loser Tuesday with a decline of 1.99 per cent, as Barrick Gold Corp. and Goldcorp Inc. both fell over 4.7 percent.

Register with us now for your free membership and gain access to our latest reports at: www.rdinvesting.com/subscribe-today/.

Barrick Gold Corp. (TSX: ABX)

Get Your Up-To-Date Barrick Gold Research Report at www.rdinvesting.com/company/ABX.

Barrick Gold’a shares fell 4.80 percent to close at C$22.81 a share Tuesday. The stock traded between C$22.62 and C$23.85 on volume of 3.70 million shares traded. The company announced that it has appointed Mark Hill as chief investment officer, effective September 12th, 2016. Consensus of analysts covering this stock has average rating as “Overweight” for the company. RBC Capital Markets analyst Stephen Walker currently has a “sector perform” rating on the stock with a price target of C$25.00. Shares of Barrick Gold have fallen gained approximately 122.7 percent year-to-date and are down roughly 20.0 percent in the past month.

Tourmaline Oil Corp. (TSX: TOU)

Get Your Up-To-Date Tourmaline Oil Research Report at www.rdinvesting.com/company/TOU.

Tourmaline Oil’s shares gained 3.06 percent to close at C$37.10 a share Tuesday. The stock traded between C$36.02 and C$37.14 on volume of 1.09 million shares traded. The company reported production averaged 190,820 barrels of oil equivalent per day for the first half of 2016, a 33-percent increase over the first half of 2015. According to Bloomberg, currently 11 analysts have “buy” ratings on the stock, while two analysts have “sell ratings”. Shares of Tourmaline Oil have gained approximately 66.0 percent year-to-date and are up roughly 10.9 percent in the past month.

Goldcorp Inc. (TSX: G)

Get Your Up-To-Date Goldcorp Research Report at www.rdinvesting.com/company/G.

Goldcorp’s shares fell 4.71 percent to close at C$20.25 a share Tuesday. The stock traded between C$20.09 and C$21.13 on volume of 3.42 million shares traded. Consensus of analyst covering this stock has “Overweight” rating on the company. On August 3rd, Citi analyst Alexander Hacking initiated coverage on Goldcorp with a “neutral” rating. The company reported gold production of 613,400 ounces at all-in sustaining costs (AISC) of $1,067 per ounce for the second quarter of 2016, compared to 908,000 ounces at AISC of $853 per ounce in 2015. Shares of Goldcorp have gained approximately 26.6 percent year-to-date, but have fallen roughly 13.2 percent in the past month.

Western Forest Products Inc. (TSE: WEF)

Get Your Up-To-Date Western Forest Products Research Report at www.rdinvesting.com/company/WEF.

Western Forest Products shares gained 1.44 percent to close at C$2.11 a share Tuesday. The stock traded between C$2.08 and C$2.11 on volume of 1.77 million shares traded. Western Forest Products announced that the chief forester of the Province of British Columbia has determined a new annual allowable cut for the company’s tree farm license 39 of 1,416,300 cubic metres. Shares of Western Forest Products have fallen approximately 6.6 percent year-to-date and are down roughly 1.4 percent in the past month.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Hemal K. Gandhi, a CFA® charter holder. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com

ReleaseID: 444563

LONDON, UK / ACCESSWIRE / August 31, 2016 / Active Wall St. announces the list of stocks for today’s research reports. Pre-market the Active Wall St. team provides the technical coverage impacting selected stocks trading on the Toronto Exchange and belonging under the Energy sector. Companies recently under review include Canadian Overseas Petroleum, Pennine Petroleum, Renaissance Oil, and Leucrotta Exploration. Get all of our free research reports by signing up at: http://www.activewallst.com/register/.

On Tuesday, August 30, 2016, at the close of the market, the TSX Venture Composite Index finished the trading session at 790.35, down 1.93%, on total volume of 171,696,310 shares.

The Energy Index closed the trading session 0.23% higher at 199.11.

Active Wall St. has initiated research reports on the following equities: Canadian Overseas Petroleum Limited (TSX-V: XOP), Pennine Petroleum Corporation (TSX-V: PNN), Renaissance Oil Corporation (TSX-V: ROE), and Leucrotta Exploration Inc. (TSX-V: LXE). Register with us now for your free membership and research reports at: http://www.activewallst.com/register/.

Canadian Overseas Petroleum Limited (TSX-V: XOP)

Calgary, Canada headquartered Canadian Overseas Petroleum Ltd.’s stock closed the day flat at $0.12. The stock recorded a trading volume of 896,398 shares, which was above its three months average volume of 719,204 shares. Shares of Canadian Overseas Petroleum, which together with its subsidiaries, engages in the identification, acquisition, exploration, and development of oil and natural gas offshore reserves in sub-Saharan Africa, have surged 33.33% in the last one month, 71.43% in the past three months and 71.43% in the previous one year. The company’s shares are trading above their 50-day and 200-day moving averages. Moreover, the stock’s 50-day moving average of $0.11 is greater than its 200-day moving average of $0.08. See our research report on XOP.V at: http://www.activewallst.com/registration-3/?symbol=XOP.

Pennine Petroleum Corporation (TSX-V: PNN)

Calgary, Canada headquartered junior oil and gas company, Pennine Petroleum Corp.’s stock finished Tuesday’s session flat at $0.03 with a total volume of 30,000 shares traded. Over the past three months and the previous one year, shares of Pennine Petroleum, which engages in the evaluation, acquisition, exploration, and development of oil and gas properties in Western Canada, have gained 50.00%, each. The Company’s shares are trading above at its 50-day and 200-day moving averages at $0.03. The complimentary research report on PNN.V at: http://www.activewallst.com/registration-3/?symbol=PNN.

Renaissance Oil Corp. (TSX-V: ROE)

On Tuesday, shares in Vancouver, Canada headquartered Renaissance Oil Corp. ended the session 2.04% lower at $0.24 with a total volume of 177,700 shares traded. Shares in Renaissance Oil, which engages in the acquisition and exploration of oil and gas properties, have rallied 140.00% in the previous three months. The stock is trading above its 200-day moving average. The company’s 50-day moving average of $0.24 is greater than its 200-day moving average of $0.14. Register for free and access the latest research report on ROE.V at: http://www.activewallst.com/registration-3/?symbol=ROE.

Leucrotta Exploration Inc. (TSX-V: LXE)

On Tuesday, shares in Calgary, Canada headquartered Leucrotta Exploration Inc. recorded a trading volume of 87,300 shares. The stock ended the day 0.48% higher at $2.09. Shares of Leucrotta Exploration, which engages in the acquisition, development, exploration, and production of oil and natural gas reserves in Canada, have gained 13.59% in the last one month and 34.84% in the previous three months. Furthermore, the stock has surged 120.00% in the past one year. The Company is trading above its 50-day and 200-day moving averages. The stock’s 50-day moving average of $1.96 is above its 200-day moving average of $1.57. Get free access to your research report on LXE.V at: http://www.activewallst.com/registration-3/?symbol=LXE.

Active Wall Street:

Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

AWS has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third party research service company (the “Reviewer”) represented by a credentialed financial analyst, for further information on analyst credentials, please email info@activewallst.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@activewallst.com

Phone number: 1-858-257-3144

Office Address: 3rd floor, 207 Regent Street, London, W1B 3HH, United Kingdom

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active Wall Street

ReleaseID: 444558

LONDON, UK / ACCESSWIRE / August 31, 2016 / Active Wall St. blog coverage looks at the headline from Mondelez International, Inc. (NASDAQ: MDLZ). For nearly two months, it was likely that the world would witness the merger of two American confectionary giants to form the world’s largest confectionery company. However, the dreams came crashing when Mondelez International, Inc. in its press release on Monday, August 29, 2016, informed Wall Street that is was no longer pursuing its bid to acquire The Hershey Company (NYSE: HSY). Register with us now for your free membership and blog access at: http://www.activewallst.com/register/.

Today, AWS is promoting its blog coverage on MDLZ and HSY. Get all of our free blog coverage and more by clicking on the link below:

http://www.activewallst.com/registration-3/?symbol=MDLZ

http://www.activewallst.com/registration-3/?symbol=HSY

Briefing and Reaction

Earlier this June, the makers of Oreo had put forward a bid of more than $23 billion for the potential takeover of Hershey. In its offer, Mondelez was to pay $107 per share in cash and stock for every Hershey’s share with an addition of 10% premium. However, the Hershey’s board then had immediately turned down the cash and stock offer and stated that “that it provided no basis for further discussion between Mondelez and the company.”

Mondelez’s CEO, Irene B. Rosenfeld, expressed her disappointment with the outcome of the talks with Hershey and stated that there was “no actionable path forward toward an agreement”. In her statement she said:

“Our proposal to acquire Hershey reflected our conviction that combining our two iconic American companies would create an industry leader with global scale in snacking and confectionery and a strong portfolio of complementary brands.”

Deal Breaking Trust

It is reckoned that the deal was abandoned after the Hershey Trust, asked the Cadbury owner to end its proposed deal with Wrigley. The Hershey Trust, established by Milton Hershey and his wife Catherine in 1905, owns 34% of the company’s common stock and yet controls 81% of the voting power. The Trust has been at the helm in turning down various offers of takeover and mergers in the past. It is regarded as the thorn when Wm. Wrigley Jr. Company offered to takeover Hershey in 2002, and was again in the line of fire when Hershey wanted to buy Cadbury eight years later but was turned down by the trust.

Meanwhile, had the deal gone through, Hershey, which generated 90% of its revenue from North America, mostly from chocolate sales, would have to give up its U.S. license for manufacturing Kit-Kat, a product of Nestle (Mondelez’s global competitor).

Stock Performance

Mondelez International’s shares ended 3.95% higher finishing the trading session at $44.74 on August 30, 2016. The stock recorded a total volume of 14.1 million shares, which was higher than its 3 months average volume of 7.36 million shares. In the last one month and the previous six months, the company’s share price has gained 2.90% and 9.46%, respectively. Currently, the stock traded at a P/E ratio of 9.63.

Following news of the failed takeover bid, The Hershey Company’s share price, on the other hand, saw a correction of 10.76% at the end of the trading session on Tuesday, 30 August, 2016, finishing the day at $99.65. The stock traded at a total volume of 7.95 million shares, which was higher than its 3 months average volume of 1.78 million shares. It is worth noting that the company’s shares were trading near their all-time high for nearly two months.

For the last month Hershey’s stock lost 9.65%, but it has advanced 9.29% in the last six months and 13.70% year-to-date.

Active Wall Street:

Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

AWS has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third party research service company (the “Reviewer”) represented by a credentialed financial analyst, for further information on analyst credentials, please email info@activewallst.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@activewallst.com

Phone number: 1-858-257-3144

Office Address: 3rd floor, 207 Regent Street, London, W1B 3HH, United Kingdom

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active Wall Street

ReleaseID: 444569

LONDON, UK / ACCESSWIRE / August 31, 2016 / Active Wall St. announces the list of stocks for today’s research reports. Pre-market the Active Wall St. team provides the technical coverage impacting selected stocks trading on the Toronto Exchange and belonging under the Technology sector. Companies recently under review include EXO U, EEStor, VersaPay, and OPSENS. Get all of our free research reports by signing up at: http://www.activewallst.com/register/.

At the closing bell on Tuesday, August 30, 2016, the TSX Venture Composite Index saw a decline of 1.93%, to end the trading session at 790.35 on a total volume of 171,696,310 shares exchanging hands for the day.

Active Wall St. has initiated research reports on the following equities: EXO U Inc. (TSX-V: EXO), EEStor Corporation (TSX-V: ESU), VersaPay Corporation (TSX-V: VPY), and OPSENS Inc. (TSX-V: OPS). Register with us now for your free membership and research reports at: http://www.activewallst.com/register/.

EXO U Inc. (TSX-V: EXO)

Montréal, Canada headquartered EXO U Inc.’s stock plummeted 25.00%, to finish Tuesday’s session at $0.03 with a total volume of 2,000 shares traded. Shares of the Company, which engages in the development of a software platform in Canada and the US, are trading below its 50-day and 200-day moving averages. EXO U’s 200-day moving average of $0.12 is above its 50-day moving average of $0.06. See our research report on EXO.V at: http://www.activewallst.com/registration-3/?symbol=EXO.

EEStor Corporation (TSX-V: ESU)

Toronto, Canada headquartered EEStor Corp.’s stock surged 15.49%, to close the day at $0.41. The stock recorded a trading volume of 89,850 shares. Shares of EEStor, which through its subsidiary, EEStor, Inc., focuses on providing edge electrical energy storage and related capacitor technologies in Canada, have rallied 51.85% in the last one month and 110.26% in the past three months. Furthermore, the stock has gained 28.13% in the previous one year. The company’s shares are trading above their 50-day and 200-day moving averages. Moreover, the stock’s 50-day moving average of $0.31 is greater than its 200-day moving average of $0.22. The complimentary research report on ESU.V at: http://www.activewallst.com/registration-3/?symbol=ESU.

VersaPay Corporation (TSX-V: VPY)

On Tuesday, shares in Toronto, Canada headquartered financial technology company, VersaPay Corp., ended the session 4.24% higher at $1.23 with a total volume of 8,000 shares traded. Shares of VersaPay, which provides cloud-based invoicing, accounts receivable management, and payment solutions for businesses in Canada and the US, have gained 14.95% in the last one month and 11.82% in the previous three months. However, the Company’s stock has fallen by 1.60% in the past one year. The stock is trading above its 50-day and 200-day moving averages. The company’s 50-day moving average of $1.13 is greater than its 200-day moving average of $1.10. Register for free and access the latest research report on VPY.V at: http://www.activewallst.com/registration-3/?symbol=VPY.

OPSENS Inc. (TSX-V: OPS)

On Tuesday, shares in Québec, Canada headquartered OPSENS Inc. recorded a trading volume of 3,100 shares. The stock ended the day flat at $1.58. OPSENS Inc.’s stock has fallen by 3.07% in the last one month and 3.07% in the previous three months. However, shares of the Company, which engages in the development, manufacture, sale, and installation of fiber optic sensors for interventional cardiology, fractional flow reserve, oil and gas, and industrial applications, have rallied 125.71% in the past one year. The Company is trading above its 200-day moving average. The stock’s 50-day moving average of $1.62 is above its 200-day moving average of $1.37. Get free access to your research report on OPS.V at: http://www.activewallst.com/registration-3/?symbol=OPS.

Active Wall Street:

Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

AWS has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third party research service company (the “Reviewer”) represented by a credentialed financial analyst, for further information on analyst credentials, please email info@activewallst.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@activewallst.com

Phone number: 1-858-257-3144

Office Address: 3rd floor, 207 Regent Street, London, W1B 3HH, United Kingdom

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active Wall Street

ReleaseID: 444557

NEW YORK, NY / ACCESSWIRE / August 31, 2016 / ImmunoCellular Therapeutics Ltd. (NYSE MKT: IMUC) shares gained 2.11 percent to close at $0.126 a share Tuesday. The stock traded between $0.12 and $0.13 on volume of 4.40 million shares traded. The stock appears to be facing some resistance at $0.13 and $0.14 with some support at $0.12. Shares of ImmunoCellular Therapeutics have fallen approximately 64.5 percent year-to-date and are down roughly 33.0 percent in the past month. Register with us now for your free membership and gain access to our latest Biotech reports at: www.rdinvesting.com/subscribe-today/.

ImmunoCellular Therapeutics Profile

ImmunoCellular Therapeutics, Ltd. is a Los Angeles-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers. The phase 3 registrational trial of lead product candidate, ICT-107, a patient-specific, dendritic cell-based immunotherapy targeting multiple tumor-associated antigens on glioblastoma stem cells, has been initiated.

ImmunoCellular’s pipeline also includes: ICT-121, a patient-specific, dendritic cell-based immunotherapy targeting the CD133 antigen on cancer stem cells in recurrent glioblastoma; ICT-140, a patient-specific, dendritic cell-based immunotherapy targeting antigens on ovarian cancer stem cells; and the Stem-to-T-cell research program which engineers the patient’s hematopoietic stem cells to generate antigen-specific cancer-killing T cells.

Get Your Up-To-Date ImmunoCellular Research Report at www.rdinvesting.com/company/IMUC.

Recent Earnings

The company reported a net loss of $5.3 million, or $0.06 per basic and diluted share, for the second quarter of 2016, compared to a net loss of $3.2 million, or $0.03 per basic and diluted share, in the second quarter of 2015. As of June 30, 2016, ImmunoCellular had $11.9 million in cash. During the second quarter 2016, ImmunoCellular incurred $4.4 million of research and development expenses.

Executive Comments

“We are pleased with the progress we made in the first half of this year, and believe that 2016 will be a year of accomplishment for our company. The first patient in the ICT-107 phase 3 trial was treated in June – a major achievement for our company. Today, more than 140 patients have been screened and clinical site activation is accelerating. We currently have activated 60 clinical sites in the US, two in Canada, and one in the UK, with more expected to come in the third quarter. With ICT-107, ImmunoCellular is one of a small number of companies in the cancer immunotherapy arena that we believe to be in the final stage of clinical development. In light of these achievements, our confidence remains high for the value and quality of our phase 3 program, and the therapeutic and commercial potential of ICT-107,” stated Andrew Gengos, ImmunoCellular Chief Executive Officer.

Get Your Up-To-Date ImmunoCellular Research Report at www.rdinvesting.com/company/IMUC.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Hemal K. Gandhi, a CFA® charter holder. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com

ReleaseID: 444564